{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T11:46:46Z","timestamp":1769428006480,"version":"3.49.0"},"reference-count":0,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Perinatal Medicine"],"published-print":{"date-parts":[[2013,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Objective:<\/jats:bold> To provide the first update on drug safety profiles and adverse drug reactions (ADRs) associated with fetal disorders from the Swiss national ADR database.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods:<\/jats:bold> We conducted a retrospective study using data from 202 pharmacovigilance reports on drug-associated fetal disorders from the Swiss national ADR database from 1990 to 2009. Evaluated aspects included administrative information on the report, drug exposure, and disorders.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results:<\/jats:bold> The ADR reporting frequency on the topic of fetal disorders has increased during the last 20 years, from only 1 report in 1991 to a maximum of 31 reports in 2008. Nervous system drugs were the most frequently reported drug group (40.2%) above all antidepressants and antiepileptics. The highest level of overall drug intake could be observed for the 1<jats:sup>st<\/jats:sup> trimester (85.4%), especially for the first 6 weeks of pregnancy. The most frequently reported types of fetal disorders were malformations (68.8%), especially those of the musculoskeletal and circulatory systems. A positive association was discovered between antiepileptics and malformations in general and in particular of the circulatory system and the eye, ear, face, and neck.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions:<\/jats:bold> The results suggest that the nervous system drug group bears an especially high risk for malformations. The most commonly identified drug exposures can help focus pharmacoepidemiologic efforts in drug-induced birth defects.<\/jats:p>","DOI":"10.1515\/jpm-2012-0091","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T16:07:29Z","timestamp":1349107649000},"page":"301-307","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders"],"prefix":"10.1515","volume":"41","author":[{"given":"Carmen","family":"Wettach","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Perinatal Pharmacology, Zurich University Hospital, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Thomann","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Perinatal Pharmacology, Zurich University Hospital, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lambrigger-Steiner","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Perinatal Pharmacology, Zurich University Hospital, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules","family":"Desmeules","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"von Mandach","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Perinatal Pharmacology, Zurich University Hospital, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2012,10,2]]},"container-title":["jpme"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2012-0091\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2012-0091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T03:21:54Z","timestamp":1678764114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2012-0091\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,2]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,12,3]]},"published-print":{"date-parts":[[2013,5,1]]}},"alternative-id":["10.1515\/jpm-2012-0091"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2012-0091","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,2]]}}}